NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), reports that the Company has filed its quarterly report with the SEC on November 23rd.
The Company reported that it had $4.2 million in cash and cash equivalents as of September 30th, 2009. The Company previously reported that it had successfully raised a total of over $4.3M in different private placement instruments. The details have been disclosed in an SEC Form 8-K filed on October 5, 2009. The Company believes it has sufficient funds to last through the end of December, 2010 at the current rate of expenditure.
The Company now has four commercially important drugs in its pipeline, targeting a total market size of approximately $40 Billion. These drugs target HIV, all Influenzas, viral diseases of the external Eye, and Herpes Simplex viral infections including cold sores and genital herpes (HSV). In addition, the Company has R&D programs in collaborations with reputed institutions against several Neglected Tropical Diseases and agents of interest for Biosecurity. These include hemorrhagic fever viruses such as Ebola/Marburg, Dengue, and Rabies, among others.
Our current drug programs include a pan-influenza drug candidate, “FluCide™”. This drug was recently reported to be highly effective against H1N1 influenza in a lethal animal model, leading to an average 14 days survival. It is generally believed that a 14 day survival in this lethal challenge model would suggest indefinite survival in other standardized animal models. FluCide is designed to be effective against all influenza A strains and mutants. We anticipate FluCide to be effective against highly pathogenic avian influenzas such as H7 and H9, the epidemic bird flu virus H5N1 (various clades), the current novel H1N1/2009 virus, seasonal influenza viruses, and their mutations.